Takeda has announced the decision to discontinue its cell therapy efforts, as part of a “strategic portfolio prioritisation process”.   The company plans to find an external partner to take over its cell therapy platform technologies and research and clinic-ready programmes in this field.   According to the announcement, Takeda has no current active clinical trials utilising […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!